MAY-17-13 Please join the Forum in congratulating Nina Mani on an exciting new career move. Nina is leaving the Forum, but she is not going far – starting June 3 she will join the FDA Center for Drug Evaluation Research, Division of Antiviral Products. That we will miss her is the understatement of the century. But the offer to join our colleagues at the FDA as a project manager presented a phenomenal opportunity – an excellent fit for her career path. We congratulate Jeff, Kim, Jules and Patrick on an excellent choice! We imagine that many of you will have the pleasure of interacting with her in her new capacity.
MAY-10-13 We are saddened to report the death of James Goodrich, PhD, MD of ViiV Healthcare, a member of the Forum’s Executive Committee. Jim passed away unexpectedly last weekend and is survived by his wife, Carolyn and two teenage daughters. A memorial service for Jim will be held this summer on a date to be determined.
Jim has been a considered and thoughtful participant on the Executive Committee. His desire to improve care for patients, direct approach and sense of humor will be missed. Please join us in keeping Jim’s family in our thoughts and prayers.
MAY-06-13 Arthur Reingold, MD, professor of epidemiology and associate dean for research at the UC Berkeley School of Public Health, was appointed to the Advisory Committee on Immunization Practices (ACIP) by Secretary Kathleen Sebelius of the Department of Health and Human Services. Learn more>>>
MAY-01-13 On behalf of the HIV/AIDS
community, the Forum for Collaborative HIV Research applauds the U.S. Preventive
Services Task Force for acting to help the estimated 1.2 million Americans now
living with HIV and especially the nearly one in five - an estimated 258,000
people - who don't know they are
infected.
APR-30-13 The USPSTF is calling for HIV screening for all Americans aged 15 to 65, regardless of whether they are considered to be at high risk, a change that may help lift some of the stigma associated with HIV testing. Read more >>
V. HCV Drug Development Advisory Group: Issues in Clinical Trial Design with DAAs, November 2010
NOV-2-10 The Fifth HCV Drug Resistance Advisory Group (HCV
DRAG) meeting was held to discuss a number of topics related to clinical
development of small molecule DAAs as well as combinations of DAAs, and
issues in Special Populations.
FDA Draft Guidance for Developing DAA Agents for Treatment of Chronic HCV Infection
SEP-14-10 Access the Food and Drug Administration (FDA)
draft guidance for direct acting antivirals (DAAs) development
for treatment of chronic hepatitis C virus infection by
clicking here.
Supplemental Materials for manuscript submitted to Gastroenterology
Click here to access Supplemental Materials submitted to Gastroenterolgoy entitled "Consensus recommendations on sequence analysis and resistance monitoring in hepatitis C virus drug development".
HCV DrAG Sponsors
The Forum is a public/private partnership. Our core funding comes from
the US federal government and from the pharmaceutical industry. The
Forum also receives grants for some projects from foundations.
HEP DART 2009, Frontiers in Drug Development for Viral Hepatitis Education Round-Table
DEC-9-09 An education roundtable was held at the HEP DART meeting in
Hawaii On Tuesday, December 8, 2009 to educate Hepatitis C virus
infected patients and update physicians who treat them about risk for,
and avoidance of drug resistance to the next generation of HCV antiviral
therapies.
IV. HCV Drug Resistance Advisory Group, November 2009
NOV-3-09 The Fourth HCV Drug Resistance Advisory Group (HCV DRAG) meeting was held to discuss HCV drug resistance issues for directly acting antivirals in clinical trials.
III. HCV Drug Resistance Advisory Group, March 2009
MAR-24-09 The HCV Drug Resistance Advisory Group (HCV DRAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006.
II. HCV Drug Resistance Advisory Group, November 2007
NOV-02-07 The HCV Drug Resistance Advisory Group (HCV DRAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006.
MAR-18-07 The HCV Drug Resistance Advisory Group (HCV DRAG) is an outgrowth of a proposal from the 1st International Workshop on Hepatitis C: Resistance and New Compounds in October 2006.
